The Supreme Court re-enters the contentious legal battle over abortion on Tuesday as it weighs restrictions on the drug that is most widely used in the United States to terminate pregnancies.
The conservative-dominated court, which overturned the constitutional right to abortion nearly two years ago is to hear oral arguments on access to the abortion pill mifepristone.
Anti-abortion groups are seeking to have the drug banned, claiming that despite its long track record it is unsafe.
Mifepristone was approved by the Food and Drug Administration in 2000 and the FDA estimates that more than 5.9 million Americans have used it to end pregnancies since then.
The case stems from a ruling last year by a conservative US District Court judge in Texas, an appointee of former Republican president Donald Trump, that would have prohibited mifepristone.
A conservative-dominated appeals court overturned the outright ban because the statute of limitations on challenging the FDA’s approval had expired. But the court nonetheless limited access to the drug.
Danco Laboratories, the mifepristone maker, and the administration of Democratic President Joe Biden appealed the lower court’s restrictions on mifepristone to the Supreme Court.
The nation’s highest court, where conservatives wield a 6-3 majority, froze the rulings by the lower court and the drug remains on the market for the time being.
The FDA approved mifepristone for use up to seven weeks of pregnancy in 2000 and further loosened the regulations in 2016, allowing it to be used up to 10 weeks.
It lifted in-person dispensing requirements in 2021, during the Covid pandemic, allowing for the drug to be distributed by mail and prescribed remotely through telemedicine.
The appeal court decision would roll back the legal limit for use of mifepristone to seven weeks, block it from being delivered by mail and require the pill to be prescribed and administered by a doctor.
A lawyer at Covington & Burling, Lewis Grossman, who joined a group of food and drug law scholars in submitting a brief in the case to the Supreme Court, said he was reluctant to predict how the nine justices will rule.
But if the court upholds the appeals court ruling they “would be doing something that I think would be very unprecedented,” Grossman said.
“They would be imposing restrictions on the availability of a drug based on a disagreement with the scientific experts at FDA”, he added.
The latest legal skirmish over reproductive rights comes as abortion pill use is on the rise in the United States.
Medication abortion accounted for 63 percent of the abortions in the country last year, up from 53 percent in 2020, according to the Guttmacher Institute.
The actual number is likely higher, the institute said, because the figures do not take into account self-managed medication abortions outside the health care system or pills mailed to women in states where abortion is banned entirely.
“Reinstating outdated and medically unnecessary restrictions on the provision of mifepristone would negatively impact people’s lives and decrease abortion access across the country,” said Amy Friedrich-Karnik, Guttmacher’s director of federal policy.
Some 20 states have banned or restricted abortion since the Supreme Court in June 2022 overturned the landmark Roe v. Wade ruling that enshrined the constitutional right to abortion for half a century.
Polls repeatedly show a clear majority of Americans support continued access to safe abortion, even as conservative groups push to limit the procedure — or ban it outright.
The Supreme Court is expected to issue a decision on the abortion pill case by the end of June — four months before the presidential election in which abortion is almost certain to be a major topic.
AFP
